Clinical Trials Logo
  1. Home
  2. Malignant Melanoma Stage IV
  3. NCT03493230

Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT ) — MALT  

Malignant Melanoma Stage IV Clinical Trial

Official title:
Detection of Plasmatic Cell-free BRAF and NRAS Mutations: a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT )

Clinical Trial Summary

The main objective of this project is to perform a longitudinal monitoring of BRAF and NRAS cell-free DNA in a large cohort of metastatic melanomas patients before treatment and during the follow-up. Results will be compared with clinical data as imaging (based on RECIST criteria) and the activity of lactate dehydrogenase in serum (LDH).

Clinical Trial Description

During a consultation of follow-up for an advanced malignant melanoma (stage IIIb or IIIC or IV), an investigator presents the study to the patient and give him the note of information and the informed consent.

The patient can benefit from a reflexion period of of 7 days.

In case of agreement, a first blood draw will take place before initiation of any treatment. Between D15 and D30 a second blood draw will be taken. Then a blood draw will be necessary every two months until recurrence or progression of the disease for a maximum of 22 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03493230
Study type Interventional
Source Centre Hospitalier Universitaire de Nice
Contact Elodie LONG-MIRA, MD
Phone 04 92 03 88 55
Email long-mira.e@chu-nice.fr
Status Not yet recruiting
Phase N/A
Start date April 2018
Completion date December 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03132090 - Early Therapy Response Monitoring in Melanoma Patients Using PET/MRI N/A
Completed NCT01676779 - mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma Phase 2
Terminated NCT04577729 - The IRMI-FMT Trial N/A
Completed NCT02439411 - Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain
Completed NCT00313235 - Combined Modality Treatment for Patients With Stage IV Melanoma Phase 1/Phase 2
Recruiting NCT03166397 - Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients Phase 2
Not yet recruiting NCT05304546 - Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma Phase 2
Terminated NCT00722098 - Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients Phase 2
Terminated NCT03430947 - Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases Phase 2
Completed NCT01189383 - IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma Phase 1/Phase 2
Completed NCT01983124 - Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib Phase 2
Completed NCT01302496 - Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma Phase 2